ScTIL
/ Chineo Medical Technology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 12, 2022
A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy of ScTIL Injection (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Advanced Malignant Solid Tumors
(clinicaltrials.gov)
- P1 | N=48 | Not yet recruiting | Sponsor: Chinese Academy of Medical Sciences
New P1 trial • Gastrointestinal Cancer • Oncology • Solid Tumor • PD-1
1 to 1
Of
1
Go to page
1